{
    "nct_id": "NCT04659603",
    "official_title": "Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",
    "inclusion_criteria": "* Participant must be at least 18 years of age\n* Participants with at least one measurable lesion according to the RECIST v1.1 criteria that has not been irradiated (ie, newly arising lesions in previously irradiated areas are accepted).\n* Participants with ECOG performance status 0 to 1.\n* Evidence of metastatic disease.\n* Expression of CEACAM 5 by centrally assessed IHC assay.\n* Male and female participants willing to comply with contraceptive use consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nCohort A: mBC\n\n* Histological or cytologic diagnosis of breast cancer.\n* Have received at least 2 prior cytotoxic chemotherapy regimens for non-TNBC tumor type or at least 1 for TNBC tumor type but not more than 4 in the locally recurrent or metastatic setting.\n\nCohorts B and C: mPAC\n\n- Have confirmed diagnosis of pancreatic ductal adenocarcinoma.\n\nCohort B: mPAC:\n\n- Have documented radiographic progression or documented intolerance after at least 1 prior systemic chemotherapy line which included either gemcitabine (or relapsed within 6 months of completion of gemcitabine adjuvant therapy) or a 5-fluorouracil based regimen (including capecitabine) but no more than 2 prior chemotherapy lines for locally advanced/metastatic disease.\n\nCohort C: mPAC\n\n- Have documented radiographic progression or documented intolerance after 1st line fluoropyrimidine-containing chemotherapy (or relapsed within 6 months of completion of chemotherapy as adjuvant therapy) for locally advanced/metastatic disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Participants are excluded from the study if any of the following criteria apply:\n\n* Medical condition requiring concomitant administration of a medication with a narrow therapeutic window, that is metabolized by cytochrome P450 (CYP450), and for which a dose reduction cannot be considered.\n* Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before the first administration of study intervention.\n* Life expectancy less than 3 months.\n* Untreated brain metastases or history of leptomeningeal disease.\n* Significant concomitant illness\n* History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.\n* History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or active hepatitis A, B or C infection.\n* Non-resolution of any prior treatment-related toxicity to <Grade 2 according to NCI CTCAE v5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy (HRT).\n* Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy.\n* Use of contact lenses. Participants using contact lenses who are not willing to stop wearing them for the duration of the study intervention are excluded.\n* Concurrent treatment with any other anti cancer therapy.\n* Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for prior antitumor therapy (chemotherapy, targeted agents, immunotherapy and radiotherapy, or any investigational treatment).\n* Any prior therapy targeting CEACAM5.\n* Prior maytansinoid DM4 treatment (ADC).\n* Any major surgery within the preceding 2 weeks of the first study intervention administration.\n* Previous enrollment in this study or current participation in any other clinical study involving an investigational study treatment or any other type of medical research.\n* Poor renal function\n* Poor hepatic function\n* Poor bone marrow function\n\nCohort C: mPAC\n\n- Any previous systemic therapy with taxane or gemcitabine (for Cohort C only).\n\nThe above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.",
    "miscellaneous_criteria": ""
}